COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00207155
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : October 28, 2015
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
The purpose of this study is to predict response to Erbitux as a single agent in patients with metastatic colon cancer

Condition or disease Intervention/treatment Phase
Metastatic Colorectal Cancer Drug: Cetuximab Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 110 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Study Start Date : December 2003
Actual Primary Completion Date : February 2006
Actual Study Completion Date : February 2006

Resource links provided by the National Library of Medicine

Drug Information available for: Cetuximab

Arm Intervention/treatment
Experimental: A Drug: Cetuximab
IV solution, IV, 400 mg/m2 initial dose + 250-400 mg/m2 weekly, Weekly, Until disease progression.
Other Name: Erbitux

Primary Outcome Measures :
  1. Prediction of response to Erbitux in subjects with metastatic colorectal cancer

Secondary Outcome Measures :
  1. Radiographic Response

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Measurable disease Tumor available for biopsies. Life expectancy of at least 3 months.

Exclusion Criteria:

  • Known or documented brain metastases prior to Cetuximab therapy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00207155

Layout table for location information
United States, California
Local Institution
Duarte, California, United States
United States, Florida
Local Institution
Tampa, Florida, United States
United States, Maryland
Local Institution
Baltimore, Maryland, United States
United States, Missouri
Local Institution
St. Louis, Missouri, United States
United States, New Jersey
Local Institution
New Brunswick, New Jersey, United States
United States, New York
Local Institution
Bronx, New York, United States
United States, Ohio
Local Institution
Cincinnati, Ohio, United States
Local Institution
Cleveland, Ohio, United States
United States, Pennsylvania
Local Institution
Hershey, Pennsylvania, United States
Local Institution
Philadelphia, Pennsylvania, United States
United States, Tennessee
Local Institution
Nashville, Tennessee, United States
United States, Texas
Local Institution
San Antonio, Texas, United States
Canada, Quebec
Local Institution
Montreal, Quebec, Canada
Local Institution
Barcelona, Spain
Sponsors and Collaborators
Eli Lilly and Company
Layout table for investigator information
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Layout table for additonal information
Responsible Party: Eli Lilly and Company Identifier: NCT00207155    
Other Study ID Numbers: CA225-045
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: October 28, 2015
Last Verified: October 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Colonic Diseases
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents